INVE

Identiv is now a post-divestiture story: the September 2024 sale of the Physical Security Business for ~$143.9M in cash left a single IoT/RFID-inlay segment sitting on a fortress balance sheet. FY2025 shows $129M cash and $141M equity against just $10.6M total liabilities (0.08x liabilities/equity) — yet the market cap is only $62.5M. That means the stock trades at roughly 0.48x net cash and 0.44x book: on paper, you are buying a dollar of cash for about fifty cents. This asset floor is the entire investment case and is why the name is not a 'sell' or 'avoid' despite awful operating metrics.

The operating business, however, is genuinely poor and getting smaller. Revenue fell 19.3% to $21.5M (the fourth straight decline from $113M in FY2022), gross margin is a razor-thin 6.1%, operating margin is -103.1%, and the company posted a -$18.0M net loss with -$6.70M operating cash flow. The MD&A is candid that revenue is lumpy — customer adoption cycles run 'six months to several years,' regulated healthcare markets 'take longer,' and a mid-2025 RFID device production transition is underway. The Risk Factors flag intensifying low-price competition 'including from China' pressuring already-minimal margins, and admit the targeted medical-device market may be 'smaller than estimated' or fail to deliver the high margins management is banking on. A -$358M accumulated deficit is a long paper trail of value destruction.